 Bacterial substance and pharmaceutical composition thereof |
| AND PREFERRED EMBODIMENT The term "treatment" used herein is intended to cover all the controls of ... |
|
| Compounds, compositions, and methods for controlling biofilms |
| This invention relates to compounds, compositions, and methods for controlling biofilms. "C... |
|
| Benzylidenenorcamphor derivatives |
| What is claimed is: 1. A method for screening the skin or hair from the sun comprising applying to ... |
|
| Cosmetic compositions comprising a film-forming polymer a citric acid ester and a plasticizing agent |
| We claim: 1. A cosmetic composition for forming a film on skin, eyelashes, eyebrows, hair, or nails ... |
|
| Triazine derivatives |
| What is claimed is: 1. A cosmetic preparation, comprising at least one triazine compound of the ... |
|
| Chlorite in the treatment of neurodegenerative disease |
| The invention features methods of treating a macrophage-associated neurodegenerative disease such ... |
|
| Pharmaceutical composition using albumin as a carrier and process for producing the same |
| I claim: 1. A process for producing a pharmaceutical composition comprising mixing together at high ... |
|
| Stabilized composition of levothyroxine sodium medication and method for its production |
| OF THE INVENTION The present invention discloses a new composition for levothyroxine sodium ... |
|
|
Extended release, film-coated tablet of astemizole and pseudoephedrine
| Details |
Inventors: Gilis, Paul Marie Victor; Jans, Eugene Marie Jozef; Gijs, Guido Jozef Maria;
Assignee: Janssen Pharmaceutica N.V. (Beerse, BE)
Primary Examiner: Krass; Frederick
Assistant Examiner:
Attorney, Agent or Firm: Metz; Charles J.
The present invention is concerned with an extended release, film coated tablet comprising as active ingredients the antihistaminic, antiallergic agent astemizole and the adrenergic, decongestant agent pseudoephedrine hydrochloride and with a process of preparing such tablets. |
|
DETAILED DESCRIPTION We claim: 1.
A four-part tablet comprising: (a) an extended release matrix core comprising pseudoephedrine hydrochloride as the active ingredient, a hydrophilic polymer selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose and hydroxyethyl cellulose as matrix material and a solid diluent; (b) an extended release coating; (c) a drug coating comprising astemizole and pseudoephedrine hydrochloride as active ingredients and a hydrophilic polymer selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose and hydroxyethyl cellulose; and (d) a seal coating, wherein the proportions of pseudoephedrine in the core and in the drug coating are selected so as to provide an initial burst of pseudoephedrine from the drug coating followed by sustained release of pseudoephedrine from the core whereby effective pseudoephedrine plasma concentrations are reached within one hour and are maintained for about 24 hours.
2.
A tablet according to claim 1 wherein 75% of the available pseudoephedrine hydrochloride is in the core and the remaining 25% in the drug coating.
3.
A tablet according to claim 1 wherein the core comprises about 60 to 240 mg pseudoephedrine hydrochloride and the drug coating comprises about 20 to 80 mg pseudoephedrine hydrochloride and about 5 to 20 mg astemizole.
4.
A tablet according to claim 1 wherein the hydrophilic polymer is hydroxypropyl methylcellulose having a viscosity of about 15000 mPa.
cndot.
s and the solid diluent is lactose.
5.
A tablet according to claim 1 wherein the extended release coating comprises ethylcellulose together with hydroxypropyl methylcellulose.
6.
A tablet according to claim 1 wherein the drug coating comprises the active ingredients astemizole and pseudoephedrine hydrochloride suspended in said hydrophilic polymer.
7.
A tablet according to claim 6 wherein the drug coating further comprises a plasticizer and a surfactant.
8.
A tablet according to claim 1 wherein the seal coating comprises said hydrophilic polymer and a plasticizer
|
| Related patents |
|
|
Pseudoephedrine hydrochloride extended-release tablets
OF THE PREFERRED EMBODIMENTS In a preferred embodiment of the present invention a combination comprising at least one active ingredient together with ...
|
|
|
Orally administrable nifedipine pellet and process for the preparation thereof
OF THE EMBODIMENTS A. A Fast-Release Type of Nifedipine Pellet The fast-release type of nifedipine pellet described in this embodiment comprises: (1) a particulate core,...
|
|
|
Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
Ethylcellulose, which is a cellulose ether that is formed by the reaction of ethyl chloride with alkaline cellulose, is completely insoluble in water and ...
|
|
|
Tea catechins as cancer specific proliferation inhibitors
The invention described herein encompasses a method of treating cancer or solid tumors comprising the administration of a therapeutically effective amount of catechins, ...
|
|
|
Mucorales fungi for use in preparation of foodstuffs
OF THE INVENTION The fermentation process of the first aspect is suitably conducted in a fermenter vessel adapted for containing the aqueous liquid, such as a vat, and ...
|
|
|
Herbal-based composition for treating acute and chronic myeloid leukemia
1. A method of treating either CD33+ acute myeloid leukemia or CD33+ chronic myeloid leukemia by administering a pharmaceutically effective amount of compound 3-O-p-...
|
|
|
Stable, pulverulent lycopene formulations, comprising lycopene having a degree of crystallinity of greater than 20%
We claim: 1. A process for the preparation of stable, pulverulent lycopene formulations, comprising lycopene having a degree of crystallinity of greater than 20%, which ...
|
|
|
Cosmetic compositions with agglomerated substrates
OF PREFERRED EMBODIMENTS Below, the invention is explained in more detail by means of examples. All percentage references relate to weight (mass) unless otherwise ...
|
|
|
Emulsifier-free finely disperse systems of the oil-in-water and water-in-oil type
The invention claimed is: 1. Pickering emulsions, which are finely disperse water-in-oil or oil-in-water systems, comprising (1) an oil phase, (2) an aqueous phase, (3) ...
|
|
|
Isolates of pythium species which are antagonistic to Pythium ultimum
What is claimed is: 1. A biologically pure culture of Pythium isolate N2 having the identifying characteristics of ATCC 20692. 2. A biologically pure culture of Pythium ...
|
|
|
Weight Loss and Supplements 
